Description: A polyclonal antibody for detection of CD1A/B from Human. This CD1A/B antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CD1A/B protein at amino acid sequence of 220-270

Description: A polyclonal antibody for detection of CD1A/B from Human. This CD1A/B antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CD1A/B protein at amino acid sequence of 220-270

Description: A Rabbit Polyclonal antibody against CD1A/B from Human. This antibody is tested and validated for IHC, WB, ELISA

Description: A Rabbit Polyclonal antibody against CD1A/B from Human. This antibody is tested and validated for IHC, WB, ELISA

Description: Rabbit polyclonal to CD1A/B.

Description: Rabbit polyclonal CD1A antibody

Description: Mouse monoclonal CD1a antibody

Description: Mouse monoclonal CD1A antibody

Description: Mouse monoclonal CD1A antibody

Description: Mouse monoclonal CD1A antibody

Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000

Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200

Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: CD1a is an antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells. [UniProt]

Description: CD1a is an antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells. [UniProt]

Description: CD1a is an antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells. [UniProt]

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin.

Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin.

Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin.

Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin.

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD1A - C-terminal region. This antibody is tested and proven to work in the following applications:

Description: Mouse monoclonal CD1a antibody (FITC)

Description: Primary antibody against CD1a(O10), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), Concentration: 0.2mg/mL

Description: Primary antibody against CD1a(O10), Concentration: 0.2mg/mL

Description: Primary antibody against CD1a(66IIC7), Concentration: 0.2mg/mL

Description: Primary antibody against CD1a(66IIC7), Concentration: 0.2mg/mL

Description: Primary antibody against CD1a(O10), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(O10), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(66IIC7), 1mg/mL

Description: Primary antibody against CD1a(O10), 1mg/mL

Description: Antibody raised against CD1A

Description: Antibody raised against CD1A

Description: Mouse monoclonal to CD1A.

Description: Mouse monoclonal to CD1A.

Description: This gene encodes a member of the CD1 family of transmembrane glycoproteins, which are structurally related to the major histocompatibility complex (MHC) proteins and form heterodimers with beta-2-microglobulin. The CD1 proteins mediate the presentation of primarily lipid and glycolipid antigens of self or microbial origin to T cells. The human genome contains five CD1 family genes organized in a cluster on chromosome 1. The CD1 family members are thought to differ in their cellular localization and specificity for particular lipid ligands. The protein encoded by this gene localizes to the plasma membrane and to recycling vesicles of the early endocytic system. Alternative splicing results in multiple transcript variants.

Description: Unconjugated Mouse monoclonal to CD1a (AS1A30)

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

Description: Sum Formula: C30H25NO4; CAS# [201484-50-6]

Description: Sum Formula: C30H25NO4; CAS# [201484-50-6]

Description: Sum Formula: C30H25NO4; CAS# [201484-50-6]

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: Mouse polyclonal to CD1a

Description: Mouse polyclonal to CD1A

Description: Primary antibody against CD1a(CB-T6), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(CB-T6), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(C1A/711), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(C1A/711), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(CB-T6), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(CB-T6), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(C1A/711), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(C1A/711), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(CB-T6), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(CB-T6), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(C1A/711), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(C1A/711), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD1a(CB-T6), Biotin conjugate, Concentration: 0.1mg/mL